Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.
about
High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.ITP: hematology's Cosette from Les Misérables.Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study.Contemporary treatment of immune thrombocytopenia.Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.Management of thrombocytopenia.A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.Fatigue in immune thrombocytopenia.A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.The platelet Fc receptor, FcγRIIa.Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.How we manage immune thrombocytopenia in the elderly.Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases.Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia.Combination therapy in relapsed or refractory chronic immune thrombocytopenia: a case report and literature review.Emerging drugs for immune thrombocytopenia (ITP).Clinical updates in adult immune thrombocytopenia.Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience.Rituximab therapy in pemphigus and other autoantibody-mediated diseases.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis.Recent advances in understanding and management of acquired thrombocytopenia.Circulating level of Th17 cells is associated with sensitivity to glucocorticoids in patients with immune thrombocytopenia.Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia.Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsedprimary immune thrombocytopenia.Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety.Current and evolving treatment strategies in adult immune thrombocytopenia
P2860
Q33406310-37E67AA7-1BC1-4B97-BCA5-E2A3AA19B83FQ33406470-9AD79C36-D417-42DE-9E36-E52CA94A18A0Q33408915-6799EEAE-A10C-443D-8F77-FF7CA3C55056Q33410653-E47D4B32-AC2D-4A9F-BCEF-E4C28BF3F8C3Q33414722-81B57A2A-FB62-4961-9304-BEF391B451FFQ33416258-46FEA70F-C82B-4896-8E19-90614DE2742CQ33419712-48AFAFC4-49CF-4361-84E9-10AB5FA9096AQ33421555-A61F03DD-F177-4019-A8A0-B2C541272F76Q33422782-58D11473-B909-4FB6-A402-133B1DA4D951Q33426717-23B058F5-3B7C-408A-83BE-CBD866368567Q33427010-9DE0F8AE-2E26-4925-9C5A-3660CCB532B2Q33427336-67B21B29-E1FF-4773-BA7C-A1251456EB2CQ33431198-31791902-B7B2-4138-AE59-237CACAB638CQ33431371-44566663-CEF2-4AFF-B1D0-BE47B5925D83Q33431689-CC350558-2D5E-4568-BC56-4BD278902C2DQ33432473-57D05BE1-F625-4729-85A5-E5DD73DF2F61Q33433705-F074F0F9-7E7E-4EB8-8C49-2F8896042B67Q33439789-0FDC0E1E-7C79-46D5-BF66-102855AEDFFCQ33441061-8CD12445-5377-455D-B146-CCF6CBE80E22Q33443173-BE4A8E0E-2E5F-4228-A33A-0F9F75A34C5BQ34486116-8F8A9409-81EA-4CD5-B59A-6F358359C1A2Q37620483-AD1EB423-E9AA-4867-BEAC-0A20CD7E0808Q38530254-62F863C6-A779-479C-8A29-A76DB973A804Q47876652-6C1D7B8E-1897-4B80-9B49-C9FBB6CAABF8Q48109292-85CCA7E0-25AD-4CE2-A640-F550CBE55A4DQ48256029-8B5A3D00-9978-4E2B-B166-025738AFA0AFQ48272079-94C0E00A-46AF-4934-86C3-F05B4C12DE93Q52695218-6A8A9C7A-7FD8-4A45-B8F7-211943B45BD7Q54922450-8BCDD571-A283-4597-878A-0A5C67A1DAD7Q58775920-F5704E86-2BCA-43C7-90AA-FC10CBF5B26C
P2860
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Rituximab and dexamethasone vs ...... imary immune thrombocytopenia.
@ast
Rituximab and dexamethasone vs ...... imary immune thrombocytopenia.
@en
type
label
Rituximab and dexamethasone vs ...... imary immune thrombocytopenia.
@ast
Rituximab and dexamethasone vs ...... imary immune thrombocytopenia.
@en
prefLabel
Rituximab and dexamethasone vs ...... imary immune thrombocytopenia.
@ast
Rituximab and dexamethasone vs ...... imary immune thrombocytopenia.
@en
P2093
P50
P1433
P1476
Rituximab and dexamethasone vs ...... imary immune thrombocytopenia.
@en
P2093
Bjarne Anker Jensen
Claus Henrik Nielsen
Hans Torben Mourits-Andersen
Henrik Sverre Birgens
Herdis Larsen
Inge Helleberg Rasmussen
Lars Kjeldsen
Morten Krogh Jensen
Ove Juul Nielsen
Stanislaw Pulczynski
P304
P356
10.1182/BLOOD-2012-09-455691
P407
P577
2013-01-04T00:00:00Z